![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.538, 2007-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
FOLFOXIRI promising in metastatic colorectal cancer
Inpharma, Vol. 1, Iss. 1587, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Risperidone better value than olanzapine
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 261, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Fluticasone propionate better value than flunisolide in asthma
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 245, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Losartan better value than atenolol for stroke prevention
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 482, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Zanamivir better value than oseltamivir for flu
Inpharma, Vol. 1, Iss. 1274, 2001-01 ,pp. :